Charles Newton

Mr. Newton joined the Novavax Board of Directors in 2025, bringing over two decades of financial and executive expertise in the healthcare industry. Currently, he serves as Chief Financial Officer of Lyell Immunopharma, where he leads financial strategy and operations.

Prior to Lyell, Mr. Newton was at Bank of America Merrill Lynch, where he served as Managing Director and Co-Head of Healthcare Investment Banking in the Americas. He was also previously with Credit Suisse, Morgan Stanley and Lehman Brothers.

Mr. Newton serves as a member of the board at Coherus BioSciences and 2seventy bio, Inc.

Mr. Newton holds a Master of Business Administration from The Tuck School of Business at Dartmouth College and a Bachelor of Arts from Colby College.